- Iambic Therapeutics, a drug developer backed by chip giant Nvidia and Qatar's sovereign wealth fund, filed for a US IPO, bolstering a busy slate of biotech listings in the fall window.
- The fall IPO window has opened on a rocky footing amid uncertainty surrounding the Iran war, AI-led disruptions, rising bond yields and interest rate hikes, yet biotech listings have stayed relatively insulated from those pressures.
- Iambic's filing keeps issuance from the biotech sector flowing through the fall window even as the broader new-issue calendar absorbs macro shocks.
引述
“backed by chip giant Nvidia(NVDA.O)”